GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Hypha Labs Inc (OTCPK:DIGP) » Definitions » Buyback Yield %

Hypha Labs (Hypha Labs) Buyback Yield % : 0.00 (As of May. 15, 2024)


View and export this data going back to 2011. Start your Free Trial

What is Hypha Labs Buyback Yield %?

Buyback yield is the net repurchase of shares outstanding over the market capital of the company. It is a measure of shareholder return.

Hypha Labs's current buyback yield was 0.00%.


Hypha Labs Buyback Yield % Historical Data

The historical data trend for Hypha Labs's Buyback Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Hypha Labs Buyback Yield % Chart

Hypha Labs Annual Data
Trend Sep14 Sep15 Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23
Buyback Yield %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -11.75 -5.43 -0.67 - -

Hypha Labs Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Buyback Yield % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Hypha Labs's Buyback Yield %

For the Diagnostics & Research subindustry, Hypha Labs's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Hypha Labs's Buyback Yield % Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Hypha Labs's Buyback Yield % distribution charts can be found below:

* The bar in red indicates where Hypha Labs's Buyback Yield % falls into.



Hypha Labs Buyback Yield % Calculation

Buyback yield is a measure of shareholder return.

Hypha Labs's Buyback Yield for the fiscal year that ended in Sep. 2023 is calculated as

Buyback Yield=Net Issuance of Stock / Market Cap
=- (Repurchase of Stock + Issuance of Stock) / Market Cap
=- (0 + 0) / 1.28903264
=0.00%

Hypha Labs's annualized Buyback Yield for the quarter that ended in Dec. 2023 is calculated as

Buyback Yield=Net Issuance of Stock(Annualized) / Market Cap
=- (Repurchase of Stock + Issuance of Stock) * Annualized Factor / Market Cap
=- (0 + 0) * 4 / 3.483872
=0.00%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In calculating the annualized quarterly data, the Repurchase of Stock and Issuance of Stock data used here is four times the quarterly (Dec. 2023) data.


Hypha Labs Buyback Yield % Related Terms

Thank you for viewing the detailed overview of Hypha Labs's Buyback Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.


Hypha Labs (Hypha Labs) Business Description

Traded in Other Exchanges
N/A
Address
6450 Cameron Street, Suite 113, Las Vegas, NV, USA, 89118
DigiPath Inc is engaged in providing pharmaceutical-grade analysis and testing cannabis education and training and brings unbiased cannabis news coverage to the cannabis industry. It screens medicinal cannabis for potentially harmful contaminants, including solvents, pesticides, mold and yeast, heavy metals such as mercury, arsenic, cadmium, and others. It also tests cannabis for its quality, potency, and cannabinoid and terpene profiles, which determine the suitability of specific cannabis strains for the treatment of specific ailments.
Executives
A Stone Douglass director 10200 WILLOW CREEK ROAD, SAN DIEGO CA 92131
Edmond Defrank director 19360 RINALDI STREET, #448, NORTHRIDGE CA 91326
Kyle Remenda officer: Chief Executive Officer 111-2532 SHORELINE DRIVE, LAKE COUNTRY A1 V4V2R6
Dennis Hartmann director 1600 CAMDEN AVENUE, NO. 103, LOS ANGELES CA 90025
Bruce I Raben director 430 VICTORIA TERRACE, RIDGEFIELD NJ 7657
Cindy Sue Orser director 4507 APPLE WAY, BOULDER CO 80301
Alfredo Axtmayer director 287 PAYNE DRIVE, CHESHIRE CT 06410
Joseph J Bianco director 611 BROADWAY,, SUITE 307, NEW YORK NY 10012
Todd A Peterson officer: Chief Financial Officer 3608 MALLARDWOOD DRIVE, LAS VEGAS NV 89129
Joe D Tanner director 28720 ROADSIDE DRIVE, SUITE 128, AGOURA HILLS CA 91301
Raw Alternative, Llc 10 percent owner 16030 VENTURA BLVD. SUITE 380, ENCINO CA 91436
Todd Denkin director, officer: President C/O PHOTOTRON, INC., 20259 VENTURA BLVD., WOODLAND HILLS CA 91364
Barbee Denny Barbee 10 percent owner 3105 EAST CENTRAL, #114, WICHITA KS 67214
Eric Stoppenhagen director, 10 percent owner, officer: CFO 8908 SPLITARROW DRIVE, AUSTIN TX 78717